NYSE:HAE - Haemonetics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $144.80
  • Forecasted Upside: 23.17 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$117.56
▲ +0.98 (0.84%)
1 month | 3 months | 12 months
Get New Haemonetics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HAE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HAE

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$144.80
▲ +23.17% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Haemonetics in the last 3 months. The average price target is $144.80, with a high forecast of $155.00 and a low forecast of $140.00. The average price target represents a 23.17% upside from the last price of $117.56.
Buy
The current consensus among 4 contributing investment analysts is to buy stock in Haemonetics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/22/2019
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/20/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/19/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/18/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/16/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/14/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/15/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/14/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/12/2021Raymond JamesBoost Price TargetOutperform$145.00 ➝ $155.00Low
i
2/3/2021Morgan StanleyBoost Price TargetOverweight$139.00 ➝ $147.00Low
i
2/3/2021Raymond JamesBoost Price TargetOutperform$135.00 ➝ $145.00Low
i
2/3/2021Barrington ResearchUpgradeMarket Perform ➝ Outperform$140.00Low
i
Rating by M. Petusky at Barrington Research
1/21/2021JMP SecuritiesBoost Price Target$110.00 ➝ $140.00Medium
i
1/21/2021Barrington ResearchDowngradeOutperform ➝ Market PerformHigh
i
Rating by M. Petusky at Barrington Research
1/20/2021Needham & Company LLCBoost Price TargetBuy$122.00 ➝ $142.00Medium
i
Rating by Michael Matson at Needham & Company LLC
1/7/2021Raymond JamesBoost Price TargetOutperform$130.00 ➝ $135.00N/A
i
12/15/2020Morgan StanleyBoost Price TargetOverweight$110.00 ➝ $139.00Low
i
11/5/2020Barrington ResearchUpgradeMarket Perform ➝ Outperform$106.00High
i
Rating by M. Petusky at Barrington Research
11/2/2020Raymond JamesBoost Price TargetOutperform$100.00 ➝ $130.00Low
i
9/15/2020Barrington ResearchReiterated RatingHoldLow
i
Rating by M. Petusky at Barrington Research
9/8/2020Raymond JamesBoost Price TargetOutperform$93.00 ➝ $100.00Medium
i
8/5/2020Raymond JamesLower Price TargetOutperform$113.00 ➝ $93.00Low
i
8/4/2020Needham & Company LLCReiterated RatingBuy$119.00Low
i
Rating by Michael Matson at Needham & Company LLC
7/8/2020Morgan StanleyLower Price TargetOverweight$138.00 ➝ $110.00Medium
i
7/1/2020Raymond JamesLower Price TargetOutperform$125.00 ➝ $113.00Low
i
5/29/2020Needham & Company LLCInitiated CoverageBuy$132.00Low
i
Rating by Michael Matson at Needham & Company LLC
5/6/2020Raymond JamesLower Price TargetOutperform$130.00 ➝ $125.00High
i
5/6/2020Barrington ResearchDowngradeOutperform ➝ Market PerformHigh
i
Rating by M. Petusky at Barrington Research
5/5/2020Needham & Company LLCLower Price TargetBuy$142.00 ➝ $132.00High
i
Rating by Michael Matson at Needham & Company LLC
4/7/2020Raymond JamesLower Price TargetOutperform$150.00 ➝ $130.00High
i
3/31/2020CJS SecuritiesUpgradeMarket Perform ➝ OutperformHigh
i
3/27/2020Morgan StanleyLower Price TargetOverweight$148.00 ➝ $138.00Low
i
2/5/2020Raymond JamesBoost Price TargetOutperform$145.00 ➝ $150.00High
i
2/4/2020Needham & Company LLCReiterated RatingBuy$142.00High
i
Rating by Michael Matson at Needham & Company LLC
1/23/2020Raymond JamesLower Price TargetOutperform$150.00 ➝ $145.00High
i
Rating by Lawrence Keusch at Raymond James
1/10/2020Needham & Company LLCInitiated CoverageBuy$138.00Low
i
11/4/2019Barrington ResearchReiterated RatingBuy$141.00Low
i
8/7/2019Barrington ResearchReiterated RatingOutperform ➝ Outperform$116.00 ➝ $139.00Low
i
8/7/2019Morgan StanleyBoost Price TargetOverweight$128.00 ➝ $148.00Low
i
8/7/2019Raymond JamesBoost Price TargetOutperform$110.00 ➝ $150.00Low
i
8/7/2019JMP SecuritiesBoost Price TargetOutperform$145.00Low
i
8/2/2019Jefferies Financial GroupBoost Price TargetBuy$125.00 ➝ $140.00Low
i
5/14/2019Raymond JamesUpgradeMarket Perform ➝ Outperform$110.00High
i
5/8/2019Barrington ResearchReiterated RatingOutperform ➝ Outperform$112.00 ➝ $116.00Low
i
2/6/2019Barrington ResearchBoost Price TargetOutperform ➝ Positive$112.00Low
i
10/5/2018Barrington ResearchReiterated RatingBuy$127.00High
i
8/9/2018Barrington ResearchBoost Price TargetOutperform$90.00 ➝ $118.00Low
i
8/8/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$100.00 ➝ $120.00Low
i
8/7/2018Jefferies Financial GroupReiterated RatingBuy$125.00Medium
i
6/14/2018Jefferies Financial GroupBoost Price TargetBuy ➝ Buy$95.00 ➝ $110.00Low
i
5/9/2018Barrington ResearchBoost Price TargetOutperform$90.00Low
i
5/9/2018Jefferies Financial GroupBoost Price TargetBuy$95.00Low
i
5/9/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$77.00 ➝ $100.00Low
i
2/7/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$74.00 ➝ $77.00High
i
2/7/2018Barrington ResearchReiterated RatingOutperform ➝ Outperform$57.00 ➝ $71.00High
i
Rating by M. Petusky at Barrington Research
2/7/2018JMP SecuritiesReiterated RatingOutperform$72.00High
i
2/7/2018Jefferies Financial GroupReiterated RatingBuy$80.00High
i
1/8/2018Jefferies Financial GroupBoost Price TargetTop Pick ➝ Buy$18.00 ➝ $75.00Low
i
1/2/2018Raymond JamesUpgradeUnderperform ➝ Market PerformHigh
i
1/2/2018Morgan StanleyUpgradeEqual Weight ➝ Overweight$51.00High
i
11/9/2017Morgan StanleyBoost Price TargetEqual Weight$43.00 ➝ $51.00N/A
i
11/8/2017Craig HallumReiterated RatingHold$40.00 ➝ $50.00N/A
i
11/8/2017Barrington ResearchBoost Price TargetOutperform$48.00 ➝ $57.00N/A
i
Rating by M. Petusky at Barrington Research
10/6/2017Morgan StanleyReiterated RatingEqual Weight$38.00 ➝ $43.00N/A
i
8/8/2017Barrington ResearchUpgradeMarket Perform ➝ Outperform$48.00High
i
Rating by M. Petusky at Barrington Research
7/27/2017Jefferies Financial GroupReiterated RatingBuy$48.00High
i
7/13/2017JMP SecuritiesUpgradeMarket Perform ➝ Outperform$50.00High
i
5/8/2017Jefferies Financial GroupReiterated RatingBuy$42.00Medium
i
2/7/2017Barrington ResearchDowngradeOutperform ➝ Market PerformN/A
i
Rating by M. Petusky at Barrington Research
11/8/2016Barrington ResearchUpgradeMarket Perform ➝ Outperform$41.00N/A
i
Rating by M. Petusky at Barrington Research
11/7/2016BTIG ResearchReiterated RatingNeutralN/A
i
11/7/2016BenchmarkBoost Price TargetHold$32.00 ➝ $34.00N/A
i
10/14/2016Off Wall StreetInitiated CoverageSell$24.00N/A
i
9/20/2016CJS SecuritiesDowngradeMarket Outperform ➝ Market Perform$35.00N/A
i
8/15/2016SidotiDowngradeBuy ➝ Neutral$39.00N/A
i
8/3/2016Barrington ResearchDowngradeOutperform ➝ Market PerformN/A
i
Rating by M. Petusky at Barrington Research
8/2/2016Jefferies Financial GroupBoost Price TargetBuy$32.00 ➝ $40.00N/A
i
8/2/2016BenchmarkBoost Price TargetHold$28.00 ➝ $32.00N/A
i
5/16/2016The Goldman Sachs GroupUpgradeSell ➝ Neutral$29.00N/A
i
5/15/2016BTIG ResearchReiterated RatingHoldN/A
i
Rating by Karen Koski at BTIG Research
5/12/2016Morgan StanleyReiterated RatingHoldN/A
i
Rating by James Francescone at Morgan Stanley
5/11/2016BenchmarkLower Price TargetHold$35.00 ➝ $28.00N/A
i
5/3/2016Morgan StanleyReiterated RatingHoldN/A
i
Rating by James Francescone at Morgan Stanley
5/3/2016Barrington ResearchLower Price TargetOutperform$40.00 ➝ $32.00N/A
i
4/19/2016BTIG ResearchReiterated RatingHoldN/A
i
Rating by Karen Koski at BTIG Research
(Data available from 4/14/2016 forward)
Haemonetics logo
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, the company offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $117.56
$116.14
$118.06

50 Day Range

MA: $118.43
$111.01
$131.88

52 Week Range

Now: $117.56
$74.48
$142.11

Volume

212,425 shs

Average Volume

398,996 shs

Market Capitalization

$5.97 billion

P/E Ratio

56.79

Dividend Yield

N/A

Beta

0.56

Frequently Asked Questions

What sell-side analysts currently cover shares of Haemonetics?

The following equities research analysts have issued research reports on Haemonetics in the last twelve months: Barrington Research, JMP Securities, Morgan Stanley, Needham & Company LLC, Raymond James, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for HAE.

What is the current price target for Haemonetics?

5 Wall Street analysts have set twelve-month price targets for Haemonetics in the last year. Their average twelve-month price target is $144.80, suggesting a possible upside of 23.2%. Raymond James has the highest price target set, predicting HAE will reach $155.00 in the next twelve months. JMP Securities has the lowest price target set, forecasting a price of $140.00 for Haemonetics in the next year.
View the latest price targets for HAE.

What is the current consensus analyst rating for Haemonetics?

Haemonetics currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HAE will outperform the market and that investors should add to their positions of Haemonetics.
View the latest ratings for HAE.

What other companies compete with Haemonetics?

How do I contact Haemonetics' investor relations team?

Haemonetics' physical mailing address is 125 Summer Street, Boston MA, 02110. The medical instruments supplier's listed phone number is 781-848-7100 and its investor relations email address is [email protected] The official website for Haemonetics is www.haemonetics.com.